Literature DB >> 29504168

Sequential surveillance for drug safety in a regulatory environment.

David Martin1, Joshua J Gagne2, Susan Gruber3, Rima Izem4, Jennifer C Nelson5, Michael D Nguyen6, Rita Ouellet-Hellstrom6, Sebastian Schneeweiss2, Sengwee Toh3, Alexander M Walker7.   

Abstract

Mesh：

Year:  2018        PMID： 29504168     DOI： 10.1002/pds.4407

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  4 in total

1.  Conditional power as an aid in making interim decisions in observational studies.

Authors:  Alexander Muir Walker
Journal:  Eur J Epidemiol       Date:  2018-05-28       Impact factor: 8.082

2.  Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.

Authors:  Elisabetta Patorno; Chandrasekar Gopalakrishnan; Kimberly G Brodovicz; Andrea Meyers; Dorothee B Bartels; Jun Liu; Martin Kulldorff; Sebastian Schneeweiss
Journal:  Diabetes Obes Metab       Date:  2019-05-01       Impact factor: 6.577

3.  Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases.

Authors:  Torbjörn Callréus; Tarec Christoffer El-Galaly; Mats Jerkeman; Peter de Nully Brown; Morten Andersen
Journal:  Pharmaceut Med       Date:  2019-04

4.  Surveillance of Antidepressant Safety (SADS): Active Signal Detection of Serious Medical Events Following SSRI and SNRI Initiation Using Big Healthcare Data.

Authors:  Mia Aakjær; Marie Louise De Bruin; Murat Kulahci; Morten Andersen
Journal:  Drug Saf       Date:  2021-09-08       Impact factor: 5.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.